Who
Anthony Tzeyew Cheung
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, enGene Therapeutics.
In numbers
- Trades disclosed
- 15
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Dec 2013
- Last trade
- 30 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 29 Jan 2025filed 31 Jan 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 21 Oct 2024filed 22 Oct 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 18 Mar 2024filed 20 Mar 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —52,940 at $0.00 | filing |
| 18 Mar 2024filed 20 Mar 2024 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K52,940 at $0.89 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —49,933 | filing |
| 7 Jul 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,222 | filing |
| 20 Aug 2021filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,472 | filing |
| 20 Aug 2021filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,255 | filing |
| 14 Dec 2020filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,266 | filing |
| 16 Mar 2018filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,618 | filing |
| 11 Jan 2016filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,860 | filing |
| 21 May 2015filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,876 | filing |
| 4 Dec 2013filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,940 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.